West Family Investments Inc. Boosts Stock Position in Abbott Laboratories $ABT

Posted by Stanley Muller on Sep 8th, 2026

West Family Investments Inc. increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 286.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,104 shares of the healthcare product maker’s stock after purchasing an additional 6,005 shares during the quarter. West Family Investments Inc.’s holdings in Abbott Laboratories were worth $735,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of recent analyst reports. BTIG Research raised their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. UBS Group lowered their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Bank of America cut their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Wells Fargo & Company increased their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. upped their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Get Our Latest Report on ABT

Abbott Laboratories Trading Down 2.5%

Shares of NYSE:ABT traded down $2.67 on Tuesday, reaching $105.66. 11,397,135 shares of the company traded hands, compared to its average volume of 11,627,073. The stock has a market capitalization of $182.82 billion, a P/E ratio of 34.19, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The business’s 50-day simple moving average is $105.04 and its 200 day simple moving average is $99.95. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 EPS. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.